Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07543536 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer

Name: Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer — clinical trial record (NCT07543536)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MEGA-TACT-BC3

StatusRecruiting

PhasePhase 3

SponsorSun Yat-sen University

Started2026-06-08

View on ClinicalTrials.gov ↗

Amendment history

2026-08-12

Study Status, Contacts/Locations v1

Recruitment opened

Start dateestimated 2026-05-01→confirmed 2026-06-08

Study sites1→2

2026-04-15

Original filing

Sun Yat-sen University

609 trials monitored

See 13 trials at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

HER2-Positive Cancer

324 trials monitored

See 21 trials at risk

This study aims to evaluate whether the combination of Megestrol Acetate at the initiation of Trastuzumab Deruxtecan (T-DXd) treatment can effectively prevent and alleviate T-DXd-related fatigue, thereby improving the quality of life for advanced breast cancer patients.

Trial Details

NCT Number	NCT07543536
Lead Sponsor	Sun Yat-sen University
Conditions	Advanced/Metastatic Breast Cancer, HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer
Enrollment	132 participants
Start Date	2026-06-08
Primary Completion	2029-04-01 (estimated)
Study Completion	2031-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-14